The Flagship train keeps chugging with its 'intersystems' player eyeing the clinic next year with 3 new drugs
Flagship companies like to move quickly these days. Just one day after Valo Health announced a move to Nasdaq via SPAC after its unveiling last September, another Flagship biotech is putting the finishing touches on a new fundraise.
Senda Biosciences closed their Series B on Thursday morning with $98 million in tow, the Cambridge, MA-based company said. The raise comes roughly seven and a half months since Flagship launched the biotech to explore what they call “intersystems biology,” or the connections between how humans coevolved with plants and bacteria.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
